Watch: New Cancer Drugs from Artificial Life

+ more

In 2014 artificial life was made for the first time.

Two new nucleotides were added—X and Y—to the standard four: A, G, T, C

These new nucleotides allow for the addition of unnatural amino acids to create entirely new kinds of proteins.

Now biotech company Synthorx has announced that they have developed a new cancer drug using these artificial bacteria.

Interleukin-2 has been studied for decades as an immune system-stimulating cancer therapy, but it unfortunately comes with some serious side effects and is often unpredictable.

By adding an extra unnatural amino acid to Interleukin, Synthorx created a “Synthorin” that prolongs the protein’s activity while eliminating its immune-suppressing effects.

So, it turns out that creating artificial life is more than a cool laboratory trick—it may turn out to be a great new way to create new drugs as well.

http://www.sandiegouniontribune.com/business/biotech/sd-me-synthorx-cancer-20180430-story.html

Latest

Airline Investors See a Post-Pandemic Rebound in Low-Cost Travel
April 14, 2021
(Bloomberg) -- New money is flowing to low-cost airlines in the U.S. as they take on giant carriers racing to recover from the unprecedented collapse in travel during the pandemic. Two established carriers that Read more
Cross-Sections: A New Industrialized Construction Podcast
April 14, 2021
  Cross-Sections brings to you bite-size conversations with host Anthony Gude, as he chats with colleagues and leaders in the construction and industrial ecosystem. Gude spoke with John Pugh Read more
What Regulations Will Get Drones Ready to Deliver to Your Front Door?
April 14, 2021
Both pilots and companies are navigating a thin line between security and innovation. Host Grant Guillot talks with leaders, influencers, and experts across the drone industry to guide us through the complex web of Read more